Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (high dose) Clear all
Completed Phase 2Phase 3 Interventional Results available

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 4 Interventional Results available

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

NCT02796755
View directory record Official record
Conditions
Inflammation, Fatigue
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 29, 2026, 12:02 PM EDT
Terminated Phase 3 Interventional

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

NCT00728091
View directory record Official record
Conditions
Hyponatremia, Inappropriate ADH Syndrome
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

NCT03637400
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Skin Infection
Interventions
TMP-SMX, DOXY
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
9 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Sylmar, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Safety Study of Chinese Herbal Therapy to Treat Asthma

NCT00601263
View directory record Official record
Conditions
Asthma
Interventions
Anti-Asthma Herbal Medical Intervention (ASHMI)
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 29, 2026, 12:02 PM EDT
Active, not recruiting Phase 2 Interventional

MTT for Children With ASD Who Have Gastrointestinal Disorders

NCT04182633
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota
Combination Product
Lead sponsor
Arizona State University
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 29, 2026, 12:02 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

NCT07628049
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Lenexa, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

NCT00499967
View directory record Official record
Conditions
Genital Warts
Interventions
GS-9191 ointment, GS-9191, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 29, 2026, 12:02 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

NCT05304910
View directory record Official record
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair

NCT03208920
View directory record Official record
Conditions
PAD, Abdominal Aortic Aneurysm
Interventions
Pro-Omega, ProOmega Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 29, 2026, 12:02 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of a Prebiotic Blend in Healthy Humans

NCT07514741
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Fiber Blend 1 (Low Dose), Fiber Blend 2 (High Dose), Placebo
Dietary Supplement · Other
Lead sponsor
LOAM Science
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

NCT02734849
View directory record Official record
Conditions
Nasal Polyposis
Interventions
AK001 low dose, AK001 high dose, Placebo
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 29, 2026, 12:02 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 29, 2026, 12:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)

NCT01972113
View directory record Official record
Conditions
Obesity, Insulin Resistance, Insulin Sensitivity, Prediabetes, Dyslipidemia, Diabetes
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 29, 2026, 12:02 PM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881
View directory record Official record
Conditions
Focal Seizure, Epilepsy, Focal Epilepsy
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Palmdale, California • Gulf Breeze, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

NCT01976936
View directory record Official record
Conditions
Stroke, Rhabdomyolysis, Jaundice
Interventions
Low Dose Lovastatin, Placebo, High Dose Lovastatin
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 29, 2026, 12:02 PM EDT